Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)

Commercial Launch of MuGard in Europe Ongoing

DALLAS, June 10 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC
Bulletin Board: ACCP), announced today that the Company has received issue
notifications from the United States Patent and Trademark Office that two US
patents relating to MuGard(TM), the Company's approved oral rinse product for
the management of mucositis will issue in June as US Patent numbers 7,544,348
and 7,547,433. MuGard is a novel, ready-to-use mucoadhesive oral wound rinse
for the management of oral mucositis, a debilitating side effect of many
anticancer treatments (for more information, please see
http://www.slideshare.net/accesspharma/mugard-for-oral-mucositis).

For latest information on the Company and its products, please follow Access
on Facebook and Twitter.

Access has announced that MuGard(TM) was launched in Germany, Italy, UK,
Greece and the Nordic countries by its European commercial partner, SpePharm.
Under a license from Access Pharmaceuticals Inc, SpePharm is responsible for
manufacturing, regulatory approval and commercialization in the 27 countries
of Europe. SpePharm plans to launch MuGard in the rest of Europe over the
coming 12 to 18 months. The license agreement includes royalties on net sales
to Access.

"SpePharm and Access are pleased with the commercial launch of MuGard in
Europe, and while it is still in the early days, initial feedback has been
positive," said Phillip Wise, Vice President of Business Development at
Access. "SpePharm is working hard to secure reimbursement from the individual
governmental regulators, which we believe will greatly enhance initial product
adoption and ongoing marketing efforts to reach and penetrate the target
population of patients requiring this important treatment option.," he
continued.

MuGard is a ready-to-use mucoadhesive oral wound rinse for the management of
oral mucositis, a debilitating side effect of many anticancer treatments. Up
to 40% of all patients receiving chemotherapy and/or radiotherapy develop
moderate to severe mucositis, and almost all patients receiving radiotherapy
for head and neck cancer and those undergoing stem cell transplantation
develop mucositis. Updated clinical practice guidelines for the prevention and
treatment of mucositis recommend the use of a preventive oral care regimen as
part of routine supportive care along with a therapeutic oral care regimen if
mucositis develops. The market for the treatment of oral mucositis is
estimated to be in excess of $1 billion world-wide.

MuGard forms a protective coating over the oral mucosa when swirled gently
around the mouth. In a comparison of cancer patients receiving standard
mucositis care with those patients receiving MuGard, the incidence and
severity of mucositis was significantly lower in the MuGard treated group
using a validated scale for the assessment of oral mucositis.

About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that
develops and commercializes propriety products for the treatment and
supportive care of cancer patients. Access' products include ProLindac(TM),
currently in Phase 2 clinical testing of patients with ovarian cancer, and
MuGard(TM) for the management of patients with mucositis. The company also has
other advanced drug delivery technologies including Cobalamin(TM)-mediated
targeted delivery and oral drug delivery, its proprietary nanopolymer delivery
technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a
humanized monoclonal antibody which acts as an anti-angiogenesis factor and is
targeted to breast cancer; and Thiarabine, a new generation nucleoside analog
which has demonstrated both pre-clinical and clinical activity in certain
cancers. For additional information on Access Pharmaceuticals, please visit
our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks and uncertainties. These statements include those relating to:
clinical trial plans and timelines and clinical results for ProLindac and
product candidates acquired in the MacroChem transaction, our ability to
execute licensing agreements in the future, Access' plans to continue and
initiate clinical trials, the value of its products in the market (including
MuGard and the size of the overall market for mucositis products), its ability
to achieve clinical and commercial success and its ability to successfully
develop marketed products. These statements are subject to numerous risks,
including but not limited Access' need to obtain additional financing in order
to continue the clinical trial and operations and to the risks detailed in
Access' Annual Reports on Form 10-K and other reports filed by Access with the
Securities and Exchange Commission.

SOURCE Access Pharmaceuticals, Inc.

Stephen B. Thompson, Vice President, Chief Financial Officer, Access
Pharmaceuticals, Inc., +1-214-905-5100; Investor Relations, Donald C.
Weinberger, or Diana Bittner (media), both of Wolfe Axelrod Weinberger Assoc.
LLC, +1-212-370-4500